KRAS is the most common oncogenic driver in NSCLC and is identified in up to 25% of adenocarcinomas and 3% of squamous cell carcinomas in western countries, and its frequency increases in smokers [122,123,124]. Here, KRAS is linked to non-small cell lung carcinoma.